NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules LinBilly W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Research output: Contribution to journalReview articlepeer-review

249 Scopus citations

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Original languageEnglish (US)
Pages (from-to)255-264
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this